Lara D. Veeken · 2020 · 21 citations · 15 references
MedicineRadiologyDiagnostic ImagingPulmonary Function TestingPulmonologyChest RadiologyForced Vital CapacityInterstitial Lung DiseaseInterstitial Lung Disease ImagingPulmonary AssessmentPulmonary ImagingAccessory MusclesChest Radiography FindingsDisease Extent QuantificationForced Vital Capacity ChangeInterstitial Lung Disease AssessmentMuscle AtrophyMuscle Atrophy MechanismsRespiratory Muscles
OBJECTIVE: To investigate the potential contribution of accessory respiratory muscle atrophy to the decline of forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (ILD). METHODS: This single-centre, retrospective study enrolled 36 patients with SSc-ILD who underwent serial pulmonary function tests and chest high-resolution CT (HRCT) simultaneously at an interval of 1-3 years. The total extent of ILD and chest wall muscle area at the level of the ninth thoracic vertebra on CT images were evaluated by two independent evaluators blinded to the patient information. Changes in the FVC, ILD extent, and chest wall muscle area between the two measurements were assessed in terms of their correlations. Multiple regression analysis was conducted to identify the independent contributors to FVC decline. RESULTS: Interval changes in FVC and total ILD extent were variable among patients, whereas chest wall muscle area decreased significantly with time (P=0.0008). The FVC change was negatively correlated with the change in ILD extent (r=-0.48, P=0.003) and was positively correlated with the change in the chest wall muscle area (r = 0.53, P=0.001). Multivariate analysis revealed that changes in total ILD extent and chest wall muscle area were independent contributors to FVC decline. CONCLUSION: In patients with SSc-ILD, FVC decline is attributable not only to the progression of ILD but also to the atrophy of accessory respiratory muscles. Our findings call attention to the interpretation of FVC changes in patients with SSc-ILD.
15
F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Annals of the Rheumatic Diseases · 2013 · 2.9K citations
Cyclophosphamide versus Placebo in Scleroderma Lung Disease
Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text
Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations